enGene Therapeutics Inc. Company Profile
NASDAQ: ENGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
enGene Therapeutics at a glance
enGene Therapeutics Inc. (NASDAQ: ENGN) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Montreal, QC, Canada. enGene Therapeutics is led by Mr. Ronald H. W. Cooper and employs about 81 people. At a market capitalization of $119.3 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001980845, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does enGene Therapeutics do?
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Business description based on the company's public filings.
Company information
- Legal name
- enGene Therapeutics Inc.
- Ticker
- NASDAQ: ENGN
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Ronald H. W. Cooper
- Employees
- 81
- Headquarters
- 4868 Rue Levy, Montreal, QC, Canada
- Phone
- 514 332 4888
- Website
- engene.com
- Market cap
- $119.29M
- SEC CIK
- 0001980845
- Latest annual report
- 10-K/A · Feb 19, 2026
Companies similar to enGene Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TNYATenaya Therapeutics Inc. | 0.5442 | +2.02% | $122.03M | vs ENGN |
| HUMAHumacyte Inc. | 0.4471 | -5.34% | $124.20M | vs ENGN |
| LENZLENZ Therapeutics Inc. | 3.53 | -2.49% | $110.91M | vs ENGN |
| BDTXBlack Diamond Therapeutics Inc. | 1.81 | -1.09% | $103.72M | vs ENGN |
| OTLKOutlook Therapeutics Inc. | 0.564 | -4.41% | $137.30M | vs ENGN |
| AVXLAnavex Life Sciences Corp. | 1.54 | +0.65% | $142.75M | vs ENGN |
| ARMPArmata Pharmaceuticals Inc. | 3.86 | +1.31% | $143.52M | vs ENGN |
| ATRAAtara Biotherapeutics Inc. | 9.23 | -1.49% | $92.65M | vs ENGN |